GALE.SW Stock Analysis
GA
Avoid
Based on Eyestock quantitative analysis, GALE.SW`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Galenica AG engages as a health care provider in Switzerland. The company is headquartered in Bern, Bern and currently employs 5,728 full-time employees. The company went IPO on 2017-04-07. The firm's business i divided into three business sectors: Retail, Products & Brands, and Services. The firm manages a locally established pharmacies network in Switzerland. The company develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.